Uroflow Special Precautions

Prior initiation of tamsulosin therapy, the patient should be examined to exclude the possibility of other conditions such as prostate carcinoma, which can cause the same manifestations as BPH. Digital rectal examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals afterwards.
Risk of Intraoperative Floppy Iris Syndrome (IFIS): IFIS have been observed during surgical phacoemulsification in some cataract patients those receiving alpha₁-adrenergic blocker therapy at the time of cataract surgery. A small number of reported cases discontinued such therapy mostly 2-14 days prior to surgery, but occasionally 5 weeks to 9 months. In patients who have received such agents and need surgical cataract management, other modified surgical techniques should be exercised with special precaution. Discontinuing tamsulosin 1-2 weeks prior to such operation is considered helpful, but clinical benefit of this approach has not been established.
Risk of Priapism: Cases of priapism in patients taking alpha1-adrenergic blockers have been reported rarely.
Risk of Cardiovascular Adverse Effects: Postural hypotension, dizziness, vertigo, or syncope may occur in tamsulosin treated patients. Starting with the lower dose and titrate slowly may be necessary and patients should be cautioned to be aware of such adverse effects as well as measures to take if the develop (e.g., sitting, laying down).
Risk of Sensitivity Reactions: Allergic reactions including rash, pruritus, urticaria and angioedema of the tongue, lips and face have been reported with positive challenge results in some patients receiving tamsulosin. Allergic reactions to tamsulosin reported rarely in patients with history of sulfonamide hypersensitivity. Use with caution in such patients with serious or life threatening reactions.